lp-a.org · The lipoprotein(a) evidence, curated for clinicians

A newer Lp(a)-cholesterol assay adds no predictive value over standard Lp(a) mass testing, a WOSCOPS nested case-control study of 238 controls and 108 cases (Atherosclerosis 2000)

Tue, 18 Aug 2026 09:48:27 +0200

This nested case-control study within the placebo arm of the West of Scotland Coronary Prevention Study (WOSCOPS) compared a newer Lp(a)-cholesterol (Lp(a)-C) assay with routine Lp(a) mass measurements in 238 controls and 108 patients who had a serious vascular event. Lp(a) mass was measured by ELISA within 2 years of sampling and re-measured by immunoturbidimetric assay about 8 years later, alongside Lp(a)-C and apo(a) isoform size measurements on the same stored samples. Lp(a)-C and Lp(a) mass provided identical information, being equally non-discriminatory between cases and controls; the only difference between groups was the percentage of null apo(a) alleles (25.6% controls vs 19.4% cases). The findings confirm concordance between the two assay systems and show the Lp(a)-C assay adds no information beyond traditional Lp(a) mass assays, which may be faster and cheaper.

Lp(a) doubles during normal pregnancy but is not further raised by pre-eclampsia, a Scottish study of 30 women (Atherosclerosis 2000)

Tue, 18 Aug 2026 09:48:26 +0200

This study examined Lp(a) changes during normal pregnancy in 10 women followed longitudinally, and compared Lp(a) in 10 women with pre-eclampsia against 10 matched normal-pregnancy controls. Lp(a) rose steadily between 10 and 35 weeks of normal pregnancy, with the median value doubling from 14.5 to 27.0 mg/dL (P=0.01), a median rise of 190% across all subjects. No significant difference in Lp(a) was found between pre-eclampsia (median 14 mg/dL) and matched controls (median 20 mg/dL) at a median gestation of 32 weeks (P=0.57). The findings show Lp(a) roughly doubles during normal pregnancy, potentially affecting fibrinolysis, but is not significantly elevated in pre-eclampsia, suggesting Lp(a) is unlikely to play a role in that disorder pathophysiology.

Lp(a) and homocysteine together raise coronary risk nearly 5-fold in women, but not men, a study of 750 men and 403 women (Arterioscler Thromb Vasc Biol 2000)

Tue, 18 Aug 2026 09:48:24 +0200

This cross-sectional study examined 750 men and 403 women referred to a preventive cardiology clinic to test whether homocysteine and Lp(a) interact to raise coronary artery disease (CAD) risk. In women, neither isolated high homocysteine (odds ratio 1.06, P=0.89) nor isolated high Lp(a) (odds ratio 1.15, P=0.60) was associated with CAD, but both together carried a strong association (odds ratio 4.83, P=0.003), with evidence of a true interactive effect beyond additive or multiplicative expectations (P=0.03). In men, both elevated homocysteine (odds ratio 1.93, P=0.05) and elevated Lp(a) (odds ratio 1.87, P=0.01) were independent CAD risk factors, but having both together conferred no additional risk (odds ratio 2.00, P=0.09), despite odds ratios as high as 12.4 within specific age intervals. The findings show homocysteine and Lp(a) interact synergistically to raise CAD risk in women but act independently in men, offering insight into their combined role in atherosclerosis.

Homozygous familial hypercholesterolaemia nearly doubles Lp(a) compared to heterozygotes, showing a clear LDL receptor gene-dose effect, a study of 69 family members (Arterioscler Thromb Vasc Biol 2000)

Tue, 18 Aug 2026 09:48:23 +0200

This study examined how LDL receptor (LDL-R) gene mutations affect Lp(a) levels in 69 members of 22 families with familial hypercholesterolaemia (FH), including 26 homozygotes and 43 heterozygotes for FH, genotyped for LDL-R mutations, apo(a) alleles and isoforms. Confirming prior findings, FH heterozygotes had significantly higher Lp(a) than non-FH individuals, and FH homozygotes with two nonfunctional LDL-R alleles had almost twice the Lp(a) levels of heterozygotes, a difference not explained by apo(a) allele frequency differences. Comparing 40 identical-by-descent apo(a) allele pairs, those from individuals with two defective LDL-R alleles had significantly higher Lp(a) than those with only one defective allele, consistent across the full range of apo(a) allele sizes. The findings demonstrate a clear gene-dosage effect of LDL-R mutations on Lp(a) plasma concentrations.

Nephrotic syndrome flares triple Lp(a) binding to fibrin, revealing a competitive tug-of-war with plasminogen, a study of 61 children (Arterioscler Thromb Vasc Biol 2000)

Tue, 18 Aug 2026 09:48:22 +0200

This study examined competitive binding of Lp(a) and plasminogen to fibrin and cell membranes in children with idiopathic nephrotic syndrome, comparing 61 cases during a disease flare-up with 33 after 6 weeks and 42 after 6 months of remission. At flare-up, low plasminogen (median 1.34 micromol/L) and high Lp(a) (median 0.27 g/L) were accompanied by increased Lp(a) binding to fibrin (3.13) and cells (1.53) compared with control children with normal plasminogen and low Lp(a) (fibrin binding 1.31, cell binding 1.05). After 6 weeks and 6 months of remission, Lp(a) binding to fibrin decreased (to 1.7 and 1.88, respectively), correlating with falling Lp(a) concentrations and rising plasminogen levels. The findings provide the first quantitative evidence that Lp(a) binding to lysine residues on fibrin and cell surfaces depends on circulating levels of both plasminogen and Lp(a), which compete as ligands for these surfaces, a mechanism potentially relevant to Lp(a) atherothrombotic role, particularly in nephrotic patients.

Lp(a) does not correlate with coronary calcium in asymptomatic postmenopausal women, a study of 178 women (J Am Coll Cardiol 2000)

Tue, 18 Aug 2026 09:43:16 +0200

This study measured Lp(a) and cardiac risk factors in 178 asymptomatic postmenopausal women (mean age 64) to assess their relationship with coronary calcium score, measured by electron-beam computed tomography. Coronary calcium score correlated with traditional risk factors, including age, diabetes, hypertension and smoking, but not with Lp(a). This lack of correlation persisted in subgroup analyses restricted to women over 60 and to those with significant coronary calcium (score at or above 50). The findings show Lp(a) does not correlate with coronary atherosclerosis, as measured by coronary calcium deposits, in asymptomatic postmenopausal women.

Garlic supplements have no effect on Lp(a), a randomised trial of 50 hypercholesterolaemic patients (J Am Coll Cardiol 2000)

Tue, 18 Aug 2026 09:43:15 +0200

This double-blind, randomised, placebo-controlled trial tested a garlic supplement (300 mg three times daily) for 3 months in 50 moderately hypercholesterolaemic subjects (mean LDL cholesterol 166 mg/dL), classified as LDL pattern A (n=22, predominantly large LDL) or pattern B (n=28, predominantly small LDL), following a 2-month stabilisation period. Garlic treatment produced no significant change in total cholesterol, LDL cholesterol, HDL cholesterol, HDL subclass distribution, postprandial triglycerides, apolipoprotein B, Lp(a), LDL peak particle diameter, or LDL subclass distribution, in the combined group or by pattern subgroup, except for a significantly greater reduction in mean peak particle diameter in pattern A subjects on garlic or placebo (P=0.01). The findings confirm garlic therapy has no effect on major plasma lipoproteins, including Lp(a), apolipoprotein B, or LDL subclass distribution.

Oral estrogen lowers Lp(a) by 23%, linked to a doubling of IGFBP-1, a trial of 73 postmenopausal women (Atherosclerosis 2000)

Tue, 18 Aug 2026 09:43:14 +0200

This double-blind, placebo-controlled trial randomised 73 hysterectomised postmenopausal women to oral estradiol valerate 2 mg/day (n=35) or transdermal estradiol gel 1 mg/day (n=38) for 6 months, measuring IGFBP-1, IGF-I and Lp(a) at baseline, 3, and 6 months. Oral therapy increased IGFBP-1 by 104% (P<0.001) and decreased IGF-I by 13% (P<0.05), while transdermal therapy left both unchanged. Lp(a) fell by 23% (median, P<0.001) with oral therapy but was unaffected by transdermal therapy, and the change in IGFBP-1 during oral therapy inversely correlated with the change in Lp(a) (r=-0.40, P<0.05). The findings suggest oral estrogen replacement raises IGFBP-1, which may partly explain its Lp(a)-lowering effect, an effect not seen with transdermal estrogen.

Lp(a) combined with Chlamydia antibodies in immune complexes nearly quadruples heart attack risk, a Swedish study of 78 cases and 156 controls (Eur Heart J 2000)

Tue, 18 Aug 2026 09:43:13 +0200

This nested case-control study within the Vasterbotten Intervention Program and WHO MONICA project examined 78 patients with acute myocardial infarction and 156 matched controls, analysing circulating immune complexes for Chlamydia pneumoniae IgG antibodies and Lp(a). A significantly larger proportion of cases than controls had both Lp(a) at or above 13 mg/L and a C. pneumoniae IgG titre at or above 1/2 in circulating immune complexes (odds ratio 3.8). The findings suggest Lp(a) proatherogenic effects may be enhanced or partly mediated through circulating immune complexes containing C. pneumoniae-specific antibodies, potentially explaining part of the link between chronic C. pneumoniae infection and atherosclerosis.

Lp(a) predicts prior heart attack in patients with coronary spasm, a Japanese study across three patient groups (J Am Coll Cardiol 2000)

Tue, 18 Aug 2026 09:43:12 +0200

This study measured Lp(a) in 77 patients with coronary spasm without significant fixed stenosis, 177 with fixed stenosis without rest angina, and 81 controls without coronary disease, to test whether Lp(a) predicts acute myocardial infarction (AMI) in coronary spasm patients. Median Lp(a) was higher in coronary spasm patients (17 mg/dL) than controls (12 mg/dL, P<0.01), but lower than in fixed-stenosis patients (23 mg/dL, P<0.01). Elevated Lp(a) (above 25 mg/dL) was more common in fixed-stenosis patients (46%, P<0.01) but not coronary spasm patients (27%) compared with controls (21%). Among coronary spasm patients, elevated Lp(a) was more frequent in those with prior myocardial infarction (56% vs 21%, P<0.05), and patients with elevated Lp(a) had a higher rate of prior MI (41% vs 13%, P<0.05); multivariate analysis confirmed elevated Lp(a) as an independent predictor of prior MI (odds ratio 4.19, 95% CI 1.03-17.00). The findings show elevated Lp(a) is associated with prior myocardial infarction in coronary spasm patients, suggesting a role for Lp(a) in thrombotic coronary occlusion following coronary spasm.

Estrogen plus progestin lowers Lp(a) and benefits women with high baseline Lp(a) most, the HERS trial of 2763 postmenopausal women (JAMA 2000)

Tue, 18 Aug 2026 09:40:34 +0200

This analysis of the HERS trial, a randomised, blinded, placebo-controlled secondary prevention trial of 2763 postmenopausal women under 80 with coronary artery disease, examined relationships between estrogen-progestin therapy, Lp(a), and recurrent coronary heart disease (CHD) events over a mean 4.1-year follow-up. Among women on placebo, higher baseline Lp(a) quartiles carried increasing relative hazards for CHD events (1.01, 1.31, and 1.54 versus the first quartile, P for trend=.03). Estrogen plus progestin significantly reduced mean Lp(a) compared with placebo (-5.8 mg/dL vs 0.3 mg/dL, P<.001). Treatment benefit was greater in women with high baseline Lp(a): the relative hazard for treatment versus placebo was 1.49 in the lowest Lp(a) quartile but fell to 1.05, 0.78, and 0.85 in higher quartiles (P for interaction trend=.03). The findings show Lp(a) independently predicts recurrent CHD in postmenopausal women, and estrogen-progestin therapy lowers Lp(a) with a more favourable relative effect in women with higher baseline Lp(a).

Rabbits lacking a functional LDL receptor accumulate over 4 times more Lp(a), a transgenic animal study (J Lipid Res 2000)

Tue, 18 Aug 2026 09:40:33 +0200

This study created LDL receptor (LDLr)-deficient WHHL transgenic rabbits expressing human apo(a) to test whether the LDL receptor mediates Lp(a) clearance. Compared with apo(a) transgenic rabbits with normal LDLr function, plasma Lp(a) increased 2-fold in LDLr heterozygous rabbits and 4.2-fold in LDLr-deficient (homozygous WHHL) rabbits, alongside markedly increased pre-beta lipoproteins and, in the LDLr-deficient rabbits, markedly increased total cholesterol and triglycerides. Hepatic apo(a) mRNA expression was similar between WHHL and normal-LDLr transgenic rabbits, indicating the Lp(a) accumulation was not due to increased apo(a) synthesis. The findings show absence of a functional LDL receptor leads to marked Lp(a) accumulation in this rabbit model, suggesting the LDL receptor participates in Lp(a) catabolism.

Glycated Lp(a) worsens blood clot-dissolving capacity in vascular cells more than native Lp(a), a mechanistic study relevant to diabetes (Atherosclerosis 2000)

Tue, 18 Aug 2026 09:40:32 +0200

This study examined how glycation, elevated in diabetic patients, affects Lp(a) impact on fibrinolytic regulators in human vascular endothelial cells. Glycated Lp(a) significantly increased PAI-1 mRNA and protein in human umbilical vein endothelial cells (HUVEC) at 5 microgram/mL compared with equal amounts of native Lp(a), and reduced t-PA secretion and synthesis, though not its mRNA level, compared with native Lp(a). Aminoguanidine, an inhibitor of advanced glycation end product formation, normalised the PAI-1 and t-PA changes induced by glycated Lp(a), while the antioxidant butylated hydroxytoluene inhibited both native and glycated Lp(a)-induced changes. The findings show glycation amplifies Lp(a) disruption of fibrinolytic regulator production in vascular endothelial cells, potentially contributing to increased cardiovascular risk in diabetic patients with elevated Lp(a).

Lp(a) does not predict ischemic stroke in young women, a case-control study of 110 cases and 216 controls (Atherosclerosis 2000)

Tue, 18 Aug 2026 09:40:30 +0200

This population-based case-control study within the Stroke Prevention in Young Women Study measured Lp(a) in 110 women with ischemic stroke and 216 age-matched controls, drawn from surveillance of 59 hospitals across Maryland, Washington DC, Pennsylvania and Delaware. Lp(a) was higher in Black than white participants, but distribution was similar between cases and controls within each racial group. After adjustment for standard risk factors, the odds ratio for Lp(a) and stroke was 1.36 (95% CI 0.80-2.29), with no dose-response relationship across Lp(a) quintiles; only lacunar stroke patients had significantly elevated Lp(a) compared with controls among stroke subtypes. The findings show no overall association between Lp(a) and ischemic stroke in young women, failing to confirm previous suggestions of a link between Lp(a) and atherosclerotic stroke in young adults.

Vitamin C supplementation does not lower Lp(a), a randomised trial of 101 people over 8 months (Atherosclerosis 2000)

Tue, 18 Aug 2026 09:40:29 +0200

This randomised, placebo-controlled, blinded trial tested whether ascorbic acid supplementation (1 g/day) lowers plasma Lp(a) in 101 healthy men and women aged 20-69, followed for 8 months (52 placebo, 49 supplemented). Baseline Lp(a) was 0.026 g/L (placebo) and 0.033 g/L (supplemented), and after 8 months, 0.027 g/L (placebo) and 0.038 g/L (supplemented), with no significant differences between or within groups, including when restricting analysis to subjects with initial Lp(a) at or above 0.050 g/L. The findings show plasma Lp(a) is not significantly affected by ascorbic acid supplementation in healthy adults.

Lp(a) in the top third raises coronary heart disease risk by 60%, a meta-analysis of 27 prospective studies (Circulation 2000)

Tue, 18 Aug 2026 09:37:07 +0200

This meta-analysis by Danesh, Collins and Peto pooled 27 prospective studies published before 2000, with at least 1 year of follow-up, examining the association between Lp(a) and coronary heart disease (CHD). Across a weighted mean follow-up of 10 years, 5436 CHD deaths or nonfatal myocardial infarctions occurred. Comparing the top third of baseline Lp(a) with the bottom third yielded a combined risk ratio of 1.6 (95% CI 1.4-1.8, P<0.00001), with similar results restricting to 18 general-population studies (risk ratio 1.7, 95% CI 1.4-1.9, P<0.00001). No significant heterogeneity was found among the 18 population-based studies or the 9 studies of patients with prior disease, and Lp(a) was only weakly correlated with classical vascular risk factors, with adjustment for these making little difference to the risk ratios. The findings demonstrate a clear association between Lp(a) and CHD across prospective studies, though the authors note further research is needed to establish causality.

Lp(a) ability to bind lysine varies because LDL and fibronectin mask its binding site, not because of the particle itself, a mechanistic study (J Lipid Res 2000)

Tue, 18 Aug 2026 09:37:06 +0200

This study investigated why only a fraction of plasma Lp(a) (Lp[a]-Lys+) binds lysine-Sepharose in vitro, examining six individuals whose Lp(a)-Lys+ fraction ranged from about 37% to 48%. Purifying Lp(a) by density gradient ultracentrifugation, gel filtration and ion-exchange chromatography progressively increased the Lys+ fraction, while adding purified LDL or fibronectin to purified Lp(a) at a 1:1 molar ratio reduced the Lys+ fraction (maximal decreases of 34% and 20%, respectively), with both together reducing it further (45% maximally). Using recombinant apo(a), a 4-fold molar excess of LDL or fibronectin similarly reduced the Lys+ fraction by 49% and 23%. The findings suggest Lp(a) lysine-binding heterogeneity largely results from LDL and fibronectin masking the lysine-binding site in apo(a) kringle IV type 10, rather than being an intrinsic property of the lipoprotein itself.

A new antibody detects oxidized Lp(a) specifically, revealing higher levels in hypertensive patients with complications, a Japanese study (Circulation 2000)

Tue, 18 Aug 2026 09:37:05 +0200

This study developed a monoclonal antibody (161E2) targeting a synthetic peptide epitope on Lp(a) that becomes externally exposed only after oxidative modification, to create a new ELISA assay measuring oxidized Lp(a) specifically. The assay confirmed oxidized Lp(a) containing the 161E2 epitope is present in human serum, and hypertensive patients with complications had significantly higher oxidized Lp(a) than normotensive subjects (P<0.01), while native Lp(a) levels did not differ between the groups. Positive immunostaining with the 161E2 antibody was also found in human arteriosclerotic tissue. The findings demonstrate the in vivo presence of oxidized Lp(a) in atherosclerotic tissue and its elevation in hypertensive patients, potentially clarifying Lp(a) role in cardiovascular disease.

Lp(a) impairs blood vessel dilation in healthy postmenopausal women, a Dutch study of 105 women (Atherosclerosis 2000)

Tue, 18 Aug 2026 09:37:04 +0200

This Dutch study measured Lp(a) and endothelial function (flow-mediated brachial artery dilation) in 105 healthy postmenopausal women aged 52-67. Flow-mediated dilation was inversely related to log Lp(a) (mean change -2.83% per unit increase, 95% CI -5.22 to -0.43), and women with Lp(a) above 239 mg/L (upper quartile) had impaired flow-mediated dilation compared with those at or below 239 mg/L (2.4% vs 5.2%), an association unchanged after adjusting for other cardiovascular risk factors. Nitroglycerine-induced (endothelium-independent) dilation was not significantly different between high and low Lp(a) groups (8.0% vs 11.4%). The findings show elevated Lp(a) is associated with impaired endothelial function in healthy postmenopausal women, independent of conventional risk factors, suggesting Lp(a) may contribute to early vascular damage and the increased cardiovascular risk seen after menopause.

Elevated Lp(a) unexpectedly raises coronary risk in older women just as strongly as in younger men, a cohort of 918 CAD and 829 non-CAD patients (Atherosclerosis 2000)

Tue, 18 Aug 2026 09:37:02 +0200

This cross-sectional study measured baseline Lp(a) in 918 coronary artery disease (CAD) patients and 829 non-CAD patients (603 women, 1144 men) at an outpatient prevention clinic, to examine age and sex differences in Lp(a)-associated CAD risk. Elevated Lp(a) (above 30 mg/dL) was a significant risk factor in both men and women (odds ratio 1.9 each). In men 55 or younger, CAD prevalence rose from 32% to 61% as Lp(a) rose from 5 mg/dL or below to 45 mg/dL or above (P for trend<0.001, odds ratio 2.5), with no significant association in men over 55. In women, CAD risk rose from 22% to 35% in those 55 or younger, and from 38% to 63% in women over 55 (odds ratio 2.1). Both younger men and older women showed substantial risk at Lp(a) above 45 mg/dL (odds ratio 3.7 and 3.3, respectively). The findings show a newly identified Lp(a)-related risk in older women comparable to that in younger men.

Lp(a) above 450 mg/L predicts earlier restenosis after angioplasty, especially combined with anticardiolipin antibodies, a study of 167 patients (Atherosclerosis 2001)

Tue, 18 Aug 2026 09:33:21 +0200

This study measured Lp(a), fibrinolytic parameters, and anticardiolipin antibodies (aCL) in 167 patients undergoing elective balloon angioplasty without stenting, to assess their association with clinical restenosis. Over follow-up, 29 patients developed clinically relevant restenosis. Lp(a) was significantly higher in patients with restenosis than without (P<0.05), with earlier restenosis seen in those with Lp(a) above 450 mg/L; Kaplan-Meier analysis showed even earlier restenosis in patients with baseline Lp(a) above 300 mg/L combined with aCL positivity. The findings show high Lp(a) contributes to clinical restenosis after balloon angioplasty without stenting, an effect accelerated by concurrent anticardiolipin antibody positivity.

Lp(a) triples coronary risk in men with low HDL cholesterol, the PROCAM study of 788 men (J Am Coll Cardiol 2001)

Tue, 18 Aug 2026 09:33:19 +0200

This prospective study followed 788 men aged 35-65 from the Prospective Cardiovascular Munster (PROCAM) study for 10 years, comparing 44 who had a myocardial infarction with 744 who remained event-free, to assess Lp(a) as a coronary risk factor alongside traditional risk factors. Overall, men with Lp(a) at or above 0.2 g/L had 2.7 times the coronary event risk of those with lower levels (95% CI 1.4-5.2), an increase most pronounced in men with LDL cholesterol at or above 4.1 mmol/L (relative risk 2.6, 95% CI 1.2-5.7), HDL cholesterol at or below 0.9 mmol/L (relative risk 8.3, 95% CI 2.0-35.5), hypertension (relative risk 3.2, 95% CI 1.4-7.2), or in the two highest global risk quintiles (relative risk 2.7, 95% CI 1.3-5.7). The findings show Lp(a) increases coronary risk, especially in men with high LDL cholesterol, low HDL cholesterol, hypertension, or high overall cardiovascular risk.

Lp(a) is higher in heart attacks that strike in the early morning, linking it to a circadian clotting surge, a study of 42 patients (Atherosclerosis 2001)

Tue, 18 Aug 2026 09:33:18 +0200

This retrospective study compared 42 patients with acute myocardial infarction (AMI), 20 who had their attack between 6:00 and 12:00 (group A) and 22 at other times (group B), all confirmed by angiography to have total occlusion of the proximal left anterior descending artery. Serum Lp(a) and thrombin-antithrombin III complex (TAT) were both higher in group A than group B, with a significant correlation between Lp(a) and TAT in group A, and non-significant trends toward positive correlation with PAI-1 and negative correlation with t-PA. In the early-morning AMI subgroup, higher Lp(a) was associated with elevated TAT and fibrinolytic factor levels. The findings suggest Lp(a) is closely linked to the increased early-morning incidence of AMI through changes in the body prothrombotic state.

Lp(a) does not predict peripheral artery disease, unlike CRP and the cholesterol ratio, a study of 14,916 physicians (JAMA 2001)

Tue, 18 Aug 2026 09:33:16 +0200

This nested case-control study compared 11 lipid and nonlipid biomarkers, including Lp(a), as predictors of symptomatic peripheral arterial disease (PAD) in a cohort of 14,916 initially healthy US male physicians aged 40-84, with 140 who developed PAD compared to 140 matched controls over an average 9-year follow-up. Baseline Lp(a) was not significantly elevated in men who developed PAD (P=.40), unlike total cholesterol, LDL cholesterol, triglycerides, apoB-100, fibrinogen, CRP, and the total cholesterol-HDL ratio, all significantly higher in cases (P<=.02). In multivariable analysis, the total cholesterol-HDL ratio was the strongest lipid predictor (relative risk 3.9 for highest versus lowest quartile, 95% CI 1.7-8.6), and CRP the strongest nonlipid predictor (relative risk 2.8, 95% CI 1.3-5.9), with CRP significantly improving prediction beyond standard lipid screening (P<.001). The findings show Lp(a) was not a significant predictor of PAD in this cohort, whereas the total cholesterol-HDL ratio and CRP were the strongest independent predictors.

Lp(a) predicts intermittent claudication more strongly in women than men, the Edinburgh Artery Study of 1592 adults (Atherosclerosis 2001)

Tue, 18 Aug 2026 09:33:15 +0200

The Edinburgh Artery Study randomly selected 1592 adults aged 55-74 from general practices in Edinburgh, Scotland, and followed them 5 years, during which 13.4% had myocardial infarction, 9.4% intermittent claudication, and 3.7% stroke. Elevated baseline Lp(a) was associated with increased risk of myocardial infarction (relative risk 1.15, 95% CI 1.00-1.32) and intermittent claudication (relative risk 1.32, 95% CI 1.10-1.57), but not significantly with stroke (relative risk 1.24, 95% CI 0.93-1.64); after adjustment, the association persisted for intermittent claudication (relative risk 1.20, 95% CI 1.00-1.43) but became non-significant for myocardial infarction (relative risk 1.06, 95% CI 0.91-1.23). The Lp(a)-associated risk was slightly higher in women than men, especially for intermittent claudication (women relative risk 1.37, 95% CI 1.01-1.87, versus men relative risk 1.09, 95% CI 0.87-1.36). The findings show Lp(a) independently predicts cardiovascular events in both sexes, with a stronger association in women and for peripheral arterial disease than myocardial infarction or stroke.

Falling triglycerides shift Lp(a) density in step with LDL, independent of apo(a) size, a study of 75 people (Arterioscler Thromb Vasc Biol 2001)

Tue, 18 Aug 2026 09:30:51 +0200

This study examined whether metabolic events affecting LDL density also affect Lp(a) density, independent of apo(a) isoform size, in 75 subjects with Lp(a) protein levels of 7-50 mg/dL and a single apo(a) size isoform, using density gradient ultracentrifugation before and during triglyceride-lowering treatment. At baseline, Lp(a) peak density correlated strongly with LDL peak density (r=0.71, P<0.0001), and during treatment, changes in plasma triglycerides shifted Lp(a) peak density in parallel with LDL peak density, with an especially strong correlation (r=0.94, P<0.0001) in subjects with initial triglycerides around 300 mg/dL. In vitro, an apo(a) isoform with 14 kringle IV type 2 repeats incorporated similarly into LDL species across a density range of 1.035-1.057 g/mL. The findings show metabolically driven changes in Lp(a) density can occur independently of apo(a) size, a factor to consider when assessing Lp(a) cardiovascular pathogenicity in hypertriglyceridaemic patients.

About half of Lp(a) apoB comes from pre-existing LDL, not fresh liver secretion, a kinetic study of 7 people (Atherosclerosis 2001)

Tue, 18 Aug 2026 09:30:49 +0200

This kinetic study examined the metabolism of Lp(a) and other apoB-containing lipoproteins in 7 subjects with Lp(a) levels of 39-85 mg/dL, using intravenous d3-leucine, mass spectrometry, and multicompartmental modelling. ApoB in Lp(a) was secreted at 0.28 mg/kg per day, with 53% derived from preformed lipoproteins (IDL and LDL) and the remainder from apoB directly secreted by the liver. The fractional catabolic rates of apoB and apo(a) from Lp(a) were 0.27 and 0.24 pools per day, respectively, less than half the fractional catabolic rate of LDL. The findings support Lp(a) assembly as an extracellular process, with its two protein components, apo(a) and apoB, cleared from the circulation at identical rates.

Lp(a) predicts heart disease risk in both sexes, with much stronger overall risk prediction in women, the ARIC study of 12,339 people (Circulation 2001)

Tue, 18 Aug 2026 09:30:48 +0200

The Atherosclerosis Risk in Communities (ARIC) study followed 12 339 middle-aged participants free of coronary heart disease (CHD) for 10 years, during which 725 CHD events occurred, to determine optimal cholesterol levels and the added predictive value of Lp(a) and other lipids. The lowest CHD incidence occurred at the lowest LDL cholesterol quintile (median 88 mg/dL in women, 95 mg/dL in men), with relative risk rising to 2.7 in women and 2.5 in men at the highest quintile. LDL cholesterol, HDL cholesterol, and Lp(a), plus triglycerides in women only, were independent CHD predictors, giving an overall relative risk of 13.5 in women and 4.9 in men; Lp(a) was less significant in Black than white participants. HDL cholesterol subfractions and apolipoproteins A-I or B did not improve prediction. The findings show optimal LDL cholesterol is below 100 mg/dL in both sexes, with LDL cholesterol, HDL cholesterol, triglycerides and Lp(a) providing substantial CHD prediction, much higher in women than men.

Elevated Lp(a) does not predict restenosis or cardiac events after coronary angioplasty, a FLARE trial analysis of 823 patients (Atherosclerosis 2001)

Tue, 18 Aug 2026 09:30:47 +0200

This ancillary analysis of the FLARE trial (Fluvastatin Angioplasty Restenosis), a multicenter randomised study of 834 patients undergoing elective balloon angioplasty, examined whether baseline Lp(a) predicts angiographic restenosis or clinical events in 823 patients with successful angioplasty and baseline Lp(a) measurements (891 lesions analysed). No association was found between Lp(a) and quantitative or binary restenosis measures; late loss was 0.27 in the lowest Lp(a) quintile versus 0.23 in the highest (P>0.05). Elevated Lp(a) was not associated with increased risk of major coronary events over 40 weeks, with a major adverse cardiac event occurring in 24% of the lowest quintile and 26% of the highest (P>0.05). Fluvastatin did not affect Lp(a) levels. The findings show elevated Lp(a) is not associated with restenosis or clinical events after elective coronary balloon angioplasty and should not be considered a risk factor for post-angioplasty restenosis.

Anabolic steroids lower Lp(a) while testosterone suppression raises it, a study of 26 men (Atherosclerosis 2001)

Tue, 18 Aug 2026 09:30:46 +0200

This study examined the effects of androgen manipulation on Lp(a), LDL particle size and postprandial triglycerides in 9 male bodybuilders using anabolic-androgenic steroids (AAS) for a mean 6.5 weeks, 10 men with testosterone reversibly suppressed for 5 weeks using the GnRH agonist triptorelin, and 7 untreated controls. Triptorelin significantly reduced testosterone (7.32 to 1.15 ng/mL, P=0.002). With AAS use, mean HDL cholesterol, Lp(a) and postprandial triglycerides all decreased (Lp(a): 125 to 69 U/L, P=0.008), while total cholesterol and LDL cholesterol were unchanged. In the triptorelin group, mean total cholesterol, HDL cholesterol and Lp(a) all increased (Lp(a): 278 to 377 U/L, P=0.004), with LDL cholesterol and postprandial triglycerides unchanged. The findings show anabolic steroid use lowers Lp(a) and postprandial triglycerides while suppressing testosterone raises Lp(a), suggesting androgens may have a complex, potentially antiatherogenic effect on Lp(a) in predisposed individuals via AAS.

Soy protein doubles Lp(a), but alcohol-extracting it eliminates the effect, a crossover trial of 12 people (Arterioscler Thromb Vasc Biol 2002)

Tue, 18 Aug 2026 09:28:12 +0200

This crossover trial tested whether alcohol-removable components of soy protein explain its Lp(a)-raising effect, having previously found soy protein raises Lp(a) more than casein. Twelve normolipidaemic men and women consumed casein, soy protein, or alcohol-extracted soy protein liquid diets for 32 days each, separated by washout periods. Median Lp(a) was more than twofold higher after 28-32 days on soy protein than on extracted soy protein (P<0.001), while casein and extracted soy protein produced virtually identical Lp(a) levels. Switching from a self-selected diet to soy protein raised median Lp(a) by 16% after 1 week (P<0.01), before declining toward baseline, whereas extracted soy protein and casein diets never raised Lp(a) and instead lowered it by more than 60% below baseline by 28-32 days (P<0.001 and P<0.01, respectively). LDL cholesterol did not differ across the three diets. The findings show dietary soy protein raises Lp(a), an effect eliminated by alcohol extraction, and that high Lp(a) can be markedly reduced through diet.

High Lp(a) impairs new blood vessel growth after limb ischemia, but a growth-factor gene therapy restores it in mice (Circulation 2002)

Tue, 18 Aug 2026 09:28:11 +0200

This study examined whether Lp(a) impairs collateral blood vessel formation in a mouse model of peripheral arterial disease, and tested gene therapy with hepatocyte growth factor (HGF) as a treatment. Lp(a) transgenic mice showed significantly less natural blood flow recovery after arterial occlusion than non-transgenic mice, with a significant negative correlation between serum Lp(a) and blood flow recovery (P<0.05); Lp(a) also stimulated vascular smooth muscle growth via ERK phosphorylation. Intramuscular injection of HGF plasmid significantly increased blood flow even in Lp(a) transgenic mice, alongside detectable human HGF protein and significantly increased capillary density compared with controls (P<0.01). The findings show high Lp(a) impairs collateral vessel formation after limb ischemia, but HGF gene therapy can induce therapeutic angiogenesis despite elevated Lp(a), suggesting a potential treatment approach for peripheral arterial disease.

Adjusting the Friedewald LDL formula for Lp(a) does not improve heart disease risk prediction, the Quebec Cardiovascular Study of 2222 men (Atherosclerosis 2002)

Tue, 18 Aug 2026 09:28:10 +0200

This study tested whether modifying the Friedewald formula for calculating LDL cholesterol to account for Lp(a)-associated cholesterol improves ischemic heart disease (IHD) risk prediction, following 2222 men free of IHD for 5 years, during which 89 had a first IHD event. Both the standard Friedewald formula (relative risk 2.15, 95% CI 1.23-3.75) and the Lp(a)-corrected Dahlen modification (relative risk 2.18, 95% CI 1.25-3.81) showed the highest LDL cholesterol tertile roughly doubled IHD risk compared with the lowest, with no meaningful difference between methods. Lp(a) itself was not an independent predictor of IHD risk. The findings show correcting the Friedewald formula for Lp(a) does not improve IHD risk assessment.

Lp(a) raises heart disease risk especially in men with high LDL cholesterol, the PRIME Study of 9133 men (Atherosclerosis 2002)

Tue, 18 Aug 2026 09:28:08 +0200

The PRIME Study, a prospective cohort of 9133 French and Northern Irish men aged 50-59 without prior coronary heart disease (CHD), measured Lp(a) at baseline and followed participants for 5 years, during which 288 had a CHD event. Lp(a) was a significant CHD risk factor overall (P<0.0006); the highest Lp(a) quartile carried 1.56 times the relative risk of CHD versus the lowest (95% CI 1.10-2.21). A significant interaction was found between Lp(a) and LDL cholesterol: the relative risk from Lp(a) at or above 33 mg/dL rose from 0.82 (95% CI 0.28-2.44) in men with the lowest LDL cholesterol quartile (below 121 mg/dL) to 1.58 (95% CI 1.06-2.40) in the highest quartile (above 163 mg/dL). The findings confirm Lp(a), measured independent of apo(a) size, predicts CHD, particularly myocardial infarction and angina, especially in men with high LDL cholesterol.

High CRP or Lp(a), but not homocysteine, predict adverse events after coronary stenting, a study of 483 patients followed 3 years (J Am Coll Cardiol 2002)

Tue, 18 Aug 2026 09:25:35 +0200

This study followed 483 consecutive patients with stable or unstable coronary syndromes for up to three years after successful coronary stenting, to test whether CRP, Lp(a), or homocysteine predict long-term prognosis. By study end, high CRP (at or above 0.68 mg/dL, P<0.001) or high Lp(a) (at or above 25 mg/dL, P=0.003), but not homocysteine, independently predicted the composite endpoint of cardiac death, myocardial infarction, or rehospitalisation for unstable angina. High CRP also predicted 1-year clinical symptom recurrence (P<0.001) and progression of atherosclerosis to a significant lesion in a non-intervened vessel (P<0.001), but none of the markers predicted in-stent restenosis. The findings show elevated CRP or Lp(a), but not homocysteine, are associated with higher rates of late adverse events after coronary stenting, with disease progression in non-intervened vessels playing a more significant role than in-stent restenosis.

Full-dose almonds lower Lp(a) by 7.8% alongside oxidized LDL, a crossover trial of 27 people (Circulation 2002)

Tue, 18 Aug 2026 09:25:34 +0200

This randomised crossover trial compared full-dose almonds, half-dose almonds plus muffins, and full-dose whole-wheat muffins (control) as isoenergetic snacks (mean 423 kcal/day) for 1 month each in 27 hyperlipidaemic men and women. Full-dose almonds (73 g/day) produced the greatest lipid reductions: LDL cholesterol fell 4.4% on half-dose (P=0.018) and 9.4% on full-dose (P<0.001), and the LDL:HDL ratio fell 7.8% on half-dose (P=0.001) and 12.0% on full-dose (P<0.001); full-dose almonds alone also significantly reduced Lp(a) (7.8%, P=0.034) and oxidized LDL (14.0%, P<0.001), with no significant reductions on the control diet. No difference was seen in pulmonary nitric oxide between treatments. The findings show almonds, used as snacks in hyperlipidaemic diets, significantly reduce coronary heart disease risk factors including Lp(a) and oxidized LDL, likely due to their nonfat and monounsaturated fat components.

Atorvastatin lowers Lp(a) more than simvastatin, but neither affects apo(a) fragments, a double-blind trial of 391 patients (Atherosclerosis 2002)

Tue, 18 Aug 2026 09:25:33 +0200

This double-blind trial randomised 391 hypercholesterolaemic patients at high cardiovascular risk to atorvastatin 10 mg/day (n=199) or simvastatin 20 mg/day (n=192) for 6 weeks, measuring Lp(a) and apo(a) fragment levels before and after treatment. Baseline Lp(a) and apo(a) fragment levels were similar between groups. Both statins significantly reduced Lp(a) (atorvastatin: 6% reduction, P<0.001; simvastatin: 0.02% reduction, P=0.046), with the reduction independently associated with baseline Lp(a) concentration but not LDL cholesterol reduction; neither statin significantly changed apo(a) fragment levels. The findings show both atorvastatin and simvastatin significantly lower Lp(a), with a greater effect from atorvastatin, while apo(a) fragmentation remains unaffected by either statin.

High Lp(a) combined with chronic Chlamydia infection may worsen aortic valve stenosis, a Swedish study of 101 patients (Eur Heart J 2003)

Tue, 18 Aug 2026 09:25:31 +0200

This study examined Lp(a), Chlamydia pneumoniae antibodies, leptin, and tissue plasminogen activator (t-PA) as risk markers for valvular aortic stenosis (AS) in 101 patients (41 women, 60 men, mean age 71) who underwent aortic valve replacement in Umea, Sweden, and 101 age- and sex-matched controls. Lp(a) at or above 480 mg/L, C. pneumoniae IgG titre at or above 1/128, high leptin, and high t-PA were each identified as AS risk markers, with a strong synergism found between Lp(a) and C. pneumoniae IgG antibodies in circulating immune complexes. The findings suggest chronic C. pneumoniae infection and high Lp(a) may jointly aggravate aortic valve sclerosis through circulating immune complex formation, alongside an association between leptin, t-PA and AS.

A specific LPA gene haplotype raises heart attack risk in women independent of Lp(a) level, a German study of 834 MI patients and 1548 controls (Circulation 2003)

Tue, 18 Aug 2026 09:25:30 +0200

This study examined LPA gene pentanucleotide (PN) repeat and kringle IV (K4) repeat polymorphisms and Lp(a) levels in 834 myocardial infarction (MI) patients (38% women) and 1548 population-based controls. Lp(a) was inversely related to K4 and PN repeat numbers, though the PN effect was limited to those with small Lp(a) particles (8 or fewer PN repeats: 66.1 mg/dL vs more than 8 PN repeats: 8.7 mg/dL, P<0.0001). MI odds were elevated in people with small Lp(a) particles (22 or fewer K4 repeats; odds ratio 1.47 in men, 1.69 in women, P<0.002). In women, the frequent haplotype combining 8 or fewer PN and 22 or fewer K4 repeats, linked to high levels of small Lp(a) particles, carried an elevated MI odds ratio of 1.79 (P=0.01) independent of Lp(a) serum concentration. The findings show K4 and PN repeat polymorphisms largely explain Lp(a) variability, and a specific haplotype predicts MI in women independent of Lp(a) concentration, suggesting particle size itself may modulate risk.

A synthetic apoB peptide blocks Lp(a) assembly far more effectively than a standard lysine analogue, a structural study (Arterioscler Thromb Vasc Biol 2003)

Tue, 18 Aug 2026 09:22:19 +0200

This study identified which apoB sequences within the previously defined 4330-4397 region mediate noncovalent binding to apo(a) during Lp(a) assembly. Comparing human and mouse apoB sequences revealed a lysine-rich, similar stretch spanning apoB amino acids 4372-4392, predicted to form an amphipathic alpha-helix and confirmed as such by circular dichroism. A synthetic peptide spanning this apoB4372-4392 sequence bound apo(a) with high affinity, though not to Lp(a) itself, and inhibited Lp(a) assembly far more effectively than the lysine analogue epsilon-amino-n-caproic acid (IC50 40 micromol/L versus 10 mmol/L). Incorporating the apoB4372-4392 peptide onto phospholipid vesicles produced an even more potent inhibitor (IC50 4 micromol/L). The findings show the apoB4372-4392 sequence mediates initial noncovalent apo(a) binding and is a novel, effective inhibitor of Lp(a) assembly.

No single gene explains why African Americans have higher Lp(a), a genetic linkage study across three populations (J Lipid Res 2003)

Tue, 18 Aug 2026 09:22:18 +0200

This study used genetic linkage analysis to search for trans-acting genetic factors that might explain why African Americans have higher Lp(a) than white individuals, analysing non-Hispanic whites, Hispanic whites, and African Americans separately. All three groups showed highly significant linkage near the lysophosphatidic acid locus, as expected, and white populations independently showed significant linkage on chromosome 19 (LOD 3.80) and suggestive linkage on chromosomes 12 (LOD 1.60), 14 (LOD 2.56), and 19 (LOD 2.52). No linkage evidence supported the hypothesis of a single additional gene with large effects specifically segregating in African Americans that could explain their elevated Lp(a) levels. The findings suggest no single trans-acting genetic factor accounts for the higher Lp(a) levels seen in African Americans.

Swapping four lysines for serines in apoB impairs Lp(a) assembly in transgenic mice, a structural mechanistic study (J Lipid Res 2004)

Tue, 18 Aug 2026 09:22:17 +0200

This study tested whether the apoB-100 amino acid sequence 4372-4392, previously shown to bind apo(a) as a synthetic peptide, is important for Lp(a) assembly in the context of full-length apoB-100. Researchers created transgenic mice expressing a mutant human apoB-100 with all four lysine residues in the 4372-4392 sequence replaced by serines (apoB-100K4-to-S4). This mutant showed reduced capacity to form Lp(a) in vitro compared with wild-type apoB-100, and double transgenic mice expressing both the mutant apoB-100 and apo(a) had significant free apo(a) in plasma, indicating less efficient Lp(a) assembly in vivo. The findings confirm the apoB-4372-4392 sequence plays a functional role in Lp(a) assembly, both in vitro and in a living animal model.

Diet and exercise raise Lp(a) by 20% in obese African-Americans, while statins push it up 30%, a study of 343 patients (Atherosclerosis 2004)

Tue, 18 Aug 2026 09:22:16 +0200

This study measured Lp(a) and lipid profiles in 343 obese African-Americans (BMI above 30 kg/m2), with 105 completing a 3-month diet and exercise intervention. Baseline Lp(a) ranged from 1.2 to 280 mg/dL and was inversely associated with triglycerides (P<0.05). After the intervention, Lp(a) and HDL cholesterol increased by a mean of 20% and 5%, while total cholesterol, triglycerides, LDL cholesterol and BMI decreased by 7%, 10%, 11% and 8%. Women on estrogen replacement had negligible Lp(a) change, while participants taking HMG-CoA reductase inhibitors (statins) saw Lp(a) rise by 30%. The findings show that a lifestyle intervention combining diet and exercise in obese African-Americans improves most lipid parameters but paradoxically raises Lp(a), an effect more pronounced with statin use.

A low-fat diet raises Lp(a) by up to 9% and oxidized LDL by up to 27%, a dietary trial of 37 women (Arterioscler Thromb Vasc Biol 2004)

Tue, 18 Aug 2026 09:22:14 +0200

This study fed 37 healthy women two reduced-fat diets, one low in vegetables and one high in vegetables, berries and fruit, to assess effects on oxidized LDL (OxLDL-EO6) and Lp(a). Total fat intake fell from 70 g/day at baseline to 56 g (low-vegetable) and 59 g (high-vegetable), saturated fat from 28 g to 20 g and 19 g, and polyunsaturated fat rose from 11 g to 13 g and 19 g. Median plasma OxLDL-EO6 increased by 27% (P<0.01) on the low-vegetable diet and 19% (P<0.01) on the high-vegetable diet, while Lp(a) increased by 7% (P<0.01) and 9% (P=0.01), respectively. The findings show that reducing dietary fat, regardless of vegetable content, increases plasma Lp(a) and oxidized LDL.

Lp(a) impairs blood vessel function most strongly in African Americans, who have nearly 4 times higher levels than Caucasians, a multiethnic study of 89 people (J Am Coll Cardiol 2004)

Tue, 18 Aug 2026 09:19:20 +0200

This study examined Lp(a) and apolipoprotein(a) isoform size in relation to endothelial function in a multiethnic cohort of 89 healthy subjects (age 42, 50 men, 39 women) free of other cardiac risk factors, measuring flow-mediated dilation (FMD) and nitrate-induced dilation of the brachial artery. Plasma Lp(a) was lowest in Caucasians (18.3 mg/dL, n=40), intermediate in Hispanics (30.2 mg/dL, n=21), and highest in African Americans (68.8 mg/dL, n=28). Lp(a) correlated inversely with FMD (r=-0.33, P<0.005), remaining significant after adjusting for sex (P=0.002), but not with nitrate-induced dilation (r=0.06, P=0.60). Subjects with small apo(a) size (22 kringle-4 repeats or fewer) had significantly lower FMD than those with larger apo(a) (2.23% vs 6.26%, P<0.0001), regardless of Lp(a) level. The findings support an independent role for Lp(a) in atherogenesis, most evident in African Americans, partly attributable to its apo(a) component.

Angioplasty acutely raises Lp(a) by 64% and oxidized phospholipids by 36%, a mechanistic study of 141 patients (Circulation 2004)

Tue, 18 Aug 2026 09:19:19 +0200

This study measured oxidized LDL (via antibody E06), Lp(a), and related immune markers before and after percutaneous coronary intervention (PCI) in 141 patients with stable angina, sampled serially from before PCI through 6 months. OxLDL-E06 and Lp(a) significantly increased immediately after PCI, by 36% (P<0.0001) and 64% (P<0.0001) respectively, returning to baseline by 6 hours; nearly all E06-detected oxidized phospholipids were bound to Lp(a) at all time points except immediately post-PCI, and OxLDL-E06 and Lp(a) were strongly correlated (r=0.68, P<0.0001). Autoantibodies to oxidized LDL decreased while apoB immune complexes increased after PCI, both returning to baseline by 6 hours, while IgM autoantibodies peaked at 1 month and IgG autoantibodies rose steadily over 6 months. The findings show PCI acutely raises Lp(a) and oxidized phospholipids, with oxidized phospholipids transferring to Lp(a), suggesting Lp(a) may play a protective innate immune role acutely, while chronically elevated Lp(a) may instead be atherogenic as a carrier of pro-inflammatory oxidation products.

Apo(a) protein size ranges from 300 to 800 kDa, driving Lp(a) extreme variability, a review of this elusive risk factor (Arterioscler Thromb Vasc Biol 2004)

Tue, 18 Aug 2026 09:19:18 +0200

This review by Berglund and Ramakrishnan examines Lp(a), a lipoprotein found only in humans, Old World primates, and the European hedgehog, resembling LDL but containing the unique, structurally distinct protein apo(a). Variability in the apo(a) gene size produces a protein molecular weight ranging from 300 to 800 kDa, likely reflecting neutral evolution without selective advantage, and this size polymorphism drives much of Lp(a) heterogeneity, with an inverse but complex relationship between apo(a) size and Lp(a) levels; Lp(a) levels also vary between populations, with Black individuals generally having higher levels than Asian or white individuals adjusting for apo(a) size, and an upstream pentanucleotide repeat further affecting levels. Multiple meta-analyses support an association between Lp(a) and coronary artery disease, particularly for Lp(a) carried in smaller apo(a) isoforms, and Lp(a) interacts with other cardiovascular risk factors, though its underlying physiological role remains unknown.

A synthetic peptide's arginine swap cuts the dose needed to block Lp(a) assembly eight-fold, a structural study (J Lipid Res 2004)

Tue, 18 Aug 2026 09:19:17 +0200

This study examined the structural features of a synthetic apoB peptide (spanning amino acids 4372-4392) that inhibits Lp(a) assembly by disrupting apoB-apo(a) binding. A central leucine-to-proline substitution destroyed the peptide alpha-helical structure and abolished its inhibitory activity, while substituting hydrophobic residues disrupted inhibition without affecting the helical structure, showing both are needed. Replacing all four lysine residues with arginine reduced the IC50 from 40 microM to 5 microM, and complexing this arginine-substituted peptide with dimyristoylphosphatidylcholine further improved potency to an IC50 of 1 microM. The findings show the peptide alpha-helical structure combined with hydrophobic lipid-interface residues is crucial for apo(a) binding, and that arginine substitution, rather than requiring lysine specifically, produces a more effective Lp(a) assembly inhibitor.

High Lp(a) blunts insulin-enhanced coronary blood flow in young healthy men, a PET imaging study of 30 men (Atherosclerosis 2005)

Tue, 18 Aug 2026 09:19:15 +0200

This study examined myocardial vasoreactivity by positron emission tomography in 30 non-smoking healthy men (mean age 34), 9 with elevated Lp(a) (above 200 mg/L, median 317 mg/L) and 21 with normal Lp(a) (below 200 mg/L, median 57 mg/L). Basal myocardial blood flow was similar between groups, and adenosine-stimulated flow showed a non-significant trend toward reduction with high Lp(a) (3.1 vs 3.7 mL/g/min, P=0.1). During simultaneous hyperinsulinemia, adenosine-stimulated flow increased further in both groups but was significantly blunted in the high-Lp(a) group (3.7 vs 4.8 mL/g/min, P=0.03), a difference that remained significant after adjusting for BMI, HbA1c, LDL cholesterol, HDL cholesterol and blood pressure (P=0.04). The findings show even young, healthy men with Lp(a) above 200 mg/L already have impaired myocardial vasoreactivity, particularly during insulin stimulation.

Lp(a) above 30 mg/dL doubles coronary disease risk in women, tripling when combined with high fibrinogen or CRP, the Nurses' Health Study of 32,826 women (Eur Heart J 2005)

Tue, 18 Aug 2026 09:16:30 +0200

This study examined Lp(a) role in coronary heart disease (CHD) using a Kringle-independent assay in 32,826 women from the Nurses' Health Study, documenting 228 CHD events over 8 years, each matched with two controls. After adjusting for standard risk factors, Lp(a) at or above 30 mg/dL carried an odds ratio of 1.9 for CHD (95% CI 1.3-3.0) versus below 30 mg/dL. Women with both high Lp(a) (at or above 30 mg/dL) and high fibrinogen (at or above 400 mg/dL) had an odds ratio of 3.2 for CHD (95% CI 1.6-6.5, P for interaction=0.05) versus both low, and those with both high Lp(a) and high CRP (at or above 3 mg/L) had an odds ratio of 3.67 (95% CI 2.03-6.64, P for interaction=0.06) versus both low. The findings show Lp(a) above 30 mg/dL doubles CHD risk in women, an effect amplified by concurrent high fibrinogen or CRP, suggesting Lp(a) risk may involve thrombosis and inflammation beyond its cholesterol content.